If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQinetiq Regulatory News (QQ.)

Share Price Information for Qinetiq (QQ.)

Share Price is delayed by 15 minutes
Get Live Data
487.60    4.80 (0.99%)
Bid:
487.00
Ask:
487.60
Spread: 0.60 (0.123%)
Market Cap: £2.50b
QQ. Live PriceLast checked at - London Stock Exchange

Intraday Qinetiq Share Chart

Director/PDMR Shareholding

27 Jun 2024 10:00

RNS Number : 1556U
QinetiQ Group plc
27 June 2024
 

 

QinetiQ Group plc (the "Company")

Notification and public disclosure of transactions by persons discharging managerial responsibilities or persons closely associated with them

 

Vested Shares

Shares sold for Income Tax and National Insurance

Retained Shares

Steve Wadey

232,746

109,722

123,024

 

The Notification of Dealing Form for the above transaction may be found below. This notification is provided in accordance with the requirements of the UK Market Abuse Regulation.

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Steve Wadey

2.

Reason for the notification

a)

Position / status

Chief Executive Officer/Director

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

QinetiQ Group plc

b)

Legal Entity Identifier Code

213800S8OBDOZMCMUW34

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument

 

Identification code

 

 

 

QinetiQ Group plc ordinary shares of 1 pence

 

 

GB00B0WMWD03

b)

Nature of the transaction

Vesting of shares under the Deferred Share Plan (Element B of the 2017 QinetiQ Group plc Incentive Plan), sale of sufficient shares to satisfy Income Tax and National Insurance Contributions required to be withheld on release and transfer of balance subject to a two-year holding period.

 

c)

Currency

GBP - British Pound

d)

Price(s) and volume(s)

Price(s) Volume(s)

 

Vesting Nil 232,746

 

Sale of shares

To satisfy income

Tax and NICs liability £4.43508 109,722

 

Transfer of shares Nil 123,024

 

 

e)

 

Aggregated information

 

- Price

 

- Volume

 

- Total

 

 

 

 

Vesting: Price Nil / Volume: 232,746

 

Tax/NI sale: Price £4.43508 / Volume 109,722

 

Transfer: Price Nil / Volume 123,024

 

f)

Date of the transaction

2024-06-25

g)

Place of the transaction

London Stock Exchange (XLON)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSEASAWELSEIM
Date   Source Headline
19th Jan 20249:31 amRNSDirector/PDMR Shareholding
16th Jan 20247:00 amRNSQ3 Trading Update and Share Buyback Programme
10th Jan 20245:00 pmRNSDirector/PDMR Shareholding
12th Dec 20232:38 pmRNSDirector/PDMR Shareholding
12th Dec 20232:32 pmRNSDirector Declaration
22nd Nov 20238:29 amRNSHolding(s) in Company
20th Nov 20237:00 amRNS$170m US new business contract win
16th Nov 20237:00 amRNSInterim Results
13th Nov 20239:58 amRNSDirector/PDMR Shareholding
25th Oct 20237:23 amRNSInvestor Seminar
17th Oct 20238:00 amRNSDirector Declaration
11th Oct 20237:00 amRNSSecond Quarter Trading Update
10th Oct 20233:56 pmRNSDirector/PDMR Shareholding
4th Oct 20237:00 amRNS$127m contract win in the US (formerly Avantus)
3rd Oct 20237:00 amRNS$84m contract win in the US
28th Sep 20233:24 pmRNSDirector/PDMR Shareholding
12th Sep 20235:54 pmRNSDirector/PDMR Shareholding
31st Aug 20235:03 pmRNS$224m contract win in the US (formerly Avantus)
25th Aug 20232:23 pmRNSDirector/PDMR Shareholding
10th Aug 20234:31 pmRNSDirector/PDMR Shareholding
27th Jul 20234:45 pmRNSDirector/PDMR Shareholding
20th Jul 20232:00 pmRNSResult of AGM
20th Jul 20237:00 amRNSFirst Quarter Trading Update
11th Jul 20235:30 pmRNSDirector/PDMR Shareholding
21st Jun 202312:15 pmRNSDirector/PDMR Shareholding
14th Jun 202310:00 amRNSHolding(s) in Company
12th Jun 20234:00 pmRNSDirector/PDMR Shareholding
12th Jun 20232:00 pmRNSAnnual Financial Report
25th May 20237:00 amRNSResults for the year ended 31 March 2023
10th May 20234:55 pmRNSDirector/PDMR Shareholding
17th Apr 20237:00 amRNSFourth Quarter Trading Update
12th Apr 202311:35 amRNSDirector/PDMR Shareholding
5th Apr 20237:00 amRNSQinetiQ announces £259 million renewal of MSCA
30th Mar 20237:00 amRNSQinetiQ Awarded $92.6M Contract
23rd Mar 20235:00 pmRNSDirectorate Change
20th Mar 202310:30 amRNSDirector Declaration
15th Mar 20232:40 pmRNSDirector Declaration
10th Mar 20232:56 pmRNSDirector/PDMR Shareholding
17th Feb 20239:00 amRNSHolding(s) in Company
16th Feb 20237:00 amRNSGary Stewart appointed CEO for Australia Sector
10th Feb 20231:14 pmRNSDirector/PDMR Shareholding
6th Feb 20231:44 pmRNSDirector/PDMR Shareholding
18th Jan 20237:00 amRNSThird Quarter Trading Update
16th Jan 20237:00 amRNS£80m contract win with UK MOD
10th Jan 20233:43 pmRNSDirector/PDMR Shareholding
5th Jan 20232:38 pmRNSDirector Declaration
12th Dec 20225:23 pmRNSDirectorate Change
12th Dec 20221:44 pmRNSDirector/PDMR Shareholding
6th Dec 20227:00 amRNSCompletion of the acquisition of Air Affairs
23rd Nov 202212:16 pmRNSCompletion of the acquisition of Avantus

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.